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A number of single-nucleotide polymorphisms (SNPs) have been identified in the genome of
Mycobacterium bovis BCG Pasteur compared with the sequenced strain M. bovis 2122/97. The
functional consequences of many of these mutations remain to be described; however, mutations
in genes encoding regulators may be particularly relevant to global phenotypic changes such as
loss of virulence, since alteration of a regulator’s function will affect the expression of a wide range
of genes. One such SNP falls in bcg3145, encoding a member of the AfsR/DnrI/SARP class of
global transcriptional regulators, that replaces a highly conserved glutamic acid residue at position
159 (E159G) with glycine in a tetratricopeptide repeat (TPR) located in the bacterial
transcriptional activation (BTA) domain of BCG3145. TPR domains are associated with protein–
protein interactions, and a conserved core (helices T1–T7) of the BTA domain seems to be
required for proper function of SARP-family proteins. Structural modelling predicted that the
E159G mutation perturbs the third a-helix of the BTA domain and could therefore have functional
consequences. The E159G SNP was found to be present in all BCG strains, but absent from
virulent M. bovis and Mycobacterium tuberculosis strains. By overexpressing BCG3145 and
Rv3124 in BCG and H37Rv and monitoring transcriptome changes using microarrays, we
determined that BCG3145/Rv3124 acts as a positive transcriptional regulator of the
molybdopterin biosynthesis moa1 locus, and we suggest that rv3124 be renamed moaR1. The
SNP in bcg3145 was found to have a subtle effect on the activity of MoaR1, suggesting that this
mutation is not a key event in the attenuation of BCG.
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The Bacille Calmette–Gue ´rin (BCG) vaccine is a live
attenuated strain of Mycobacterium bovis derived by in vitro
passage of an M. bovis strain from 1908 to 1921 (Calmette,
1927). This in vitro cultivation led to the accumulation of
mutations in the BCG genome that attenuated the bacillus.
BCG is the only vaccine available against tuberculosis, and
with more than 3 billion individuals having been
immunized with BCG it is the most widely used vaccine
in the world (Brosch et al., 2007). Despite the widespread
use of BCG, a precise catalogue of the genetic lesions that
led to attenuation has not been defined. Knowledge of
these mutations would shed light not only on the
attenuation of BCG, but also on virulence factors of the
tubercle bacilli.
Work towards defining the attenuating genetic lesions in
BCG began with the identification of the RD1–RD3 loci
using subtractive genomic hybridization techniques
(Mahairas et al., 1996). The RD1 locus was shown to be
deleted from all BCG strains but present in all virulent
strains of M. bovis and Mycobacterium tuberculosis studied.
Subsequent work has shown that this deletion played a
major role in the attenuation of BCG (Lewis et al., 2003;
Pym et al., 2002), although restoration of RD1 by knock-in
did not restore virulence to wild-type levels in immuno-
competent mice (Pym et al., 2002), indicating that other
attenuating mutations exist. Comparative genome analyses
using genomic libraries and DNA arrays further expanded
the list of deleted regions and chromosomal rearrange-
ments between BCG and virulent M. bovis (Behr et al.,
1999; Gordon et al., 1999; Mostowy et al., 2003). However,
it was with the completion of the genome sequence of M.
bovis BCG Pasteur, and comparison with the genomes of
M. tuberculosis (Cole et al., 1998) and M. bovis (Garcia
Pelayo et al., 2009), that we obtained single-nucleotide
resolution of mutations present in BCG Pasteur. From
genome analysis, 736 single-nucleotide polymorphisms
(SNPs) were identified between BCG Pasteur and the
virulent M. bovis strain AF2122/97 (Brosch et al., 2007).
However, many of these SNPs may be specific to the BCG
Pasteur or M. bovis AF2122/97 strains sequenced. To gain a
‘minimal’ list of SNPs that differentiate attenuated BCG
from virulent M. bovis strains, Garcia Pelayo et al. (2009)
screened all SNPs present in BCG against a panel of 21
M. bovis strains and 13 BCG strains. This allowed the
identification of 186 SNPs between virulent M. bovis strains
and all BCG strains, with 115 of these SNPs being non-
synonymous (nsSNP) and hence having potential func-
tional consequences.
Previous characterization of nsSNPs in BCG has provided
key insights into gene function. The first study to link a
SNP to a phenotypic change in BCG strains examined the
mma3 gene, where a nsSNP abolished methoxymycolate
production in ‘late’ BCG strains (derived post-1927,
compared with ‘early’ strains that were derived pre-1927)
(Behr et al., 2000; Belley et al., 2004). A nsSNP in the BCG
gene encoding the CRP global gene regulator has been
shown to affect global gene regulation, but play no role in
the attenuation of BCG (Hunt et al., 2008). Furthermore a
nsSNP in the pykA gene of BCG has been shown to permit
growth of BCG on glycerol as a sole carbon source, a
mutation that was selected during growth of the M. bovis
progenitor on glycerinated potato slices (Keating et al.,
2005). Hence, determining the functional consequences of
nsSNPs found in BCG can reveal much about biological
function of the gene product as well as any role for the gene
in virulence.
One of the 186 nsSNPs between BCG and virulent M. bovis
was found in the bcg3145 gene (an orthologue of rv3124 in
M. tuberculosis). BCG3145 is a member of the AfsR/DnrI/
SARP (Streptomyces antibiotic regulatory protein) class of
transcriptional regulators. This class also contains EmbR,
the regulator of three arabinosyltransferases that are the
targets of the front-line tuberculosis drug ethambutol
(Belanger et al., 1996). The structure of EmbR has been
elucidated, revealing DNA-binding, bacterial transcrip-
tional activation (BTA), and forkhead-associated domains
(Alderwick et al., 2006). The E159G mutation in BCG3145
mutates to glycine a conserved glutamic acid residue
located in the BTA domain (region T3). However, whether
the E159G mutation affects the ability of BCG3145 to
regulate transcription, or the identity of the genes regulated
by BCG3145, was unknown. Mutations in regulatory genes
may be particularly relevant to global phenotypic changes
such as loss of virulence, since alteration of a regulator’s
function will affect the expression of a wide range of genes.
In order to define the function of BCG3145/Rv3124, we
describe here structural predictions, transcriptome analysis,
site-directed mutagenesis, gel-shift assays and promoter
reporter assays that show BCG3145/Rv3124 to be a positive
transcriptional regulator of the moa1 locus.
METHODS
Bacterial strains and growth conditions. Mycobacteria and
Escherichia coli strains used in this study are listed in Table 1.
Strains were grown in 7H9 Middlebrook broth (Becton Dickinson)
containing albumin-glucose-catalase (ADC, Becton Dickinson) (7H9-
ADC), 0.2% glycerol and 0.05% Tween 80. After electroporation of
pSM96 and derivatives, mycobacterial transformants were selected on
7H11 medium containing 10% (v/v) oleic acid-ADC (OADC, Becton
Abbreviations: BTA, bacterial transcriptional activator; DBD, DNA-
binding domain; EMSA, electrophoretic mobility shift assay; nsSNP,
non-synonymous SNP; qRT-PCR, quantitative reverse transcription PCR;
SARP, Streptomyces antibiotic regulatory protein, SNP, single-nucleotide
polymorphism.
ThearraydesignusedinthisstudyisavailableinBmG@Sbase(accessionno.
A-BUGS-31; http://bugs.sgul.ac.uk/A-BUGS-31) and also ArrayExpress
(accession no. A-BUGS-31). Fully annotated microarray data have been
deposited in BmG@Sbase (accession no. E-BUGS-93; http://bugs.sgul.ac.
uk/E-BUGS-93) and also ArrayExpress (accession no. E-BUGS-93).
Three supplementary tables and two supplementary figures are available
with the online version of this paper.
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at 25 mgm l
21, and hygromycin (Invitrogen) at 150 mgm l
21. E. coli
strains were used as a general-purpose cloning and expression host and
grown at37 uC inLuria–Bertani(LB) mediumwithshaking,and onLB
agar with ampicillin (Sigma; 100 mgm l
21), hygromycin (150 mgm l
21),
or kanamycin (25 mgm l
21) as appropriate.
Confirmation of SNP in bcg3145. A 500 bp fragment flanking the
E159G nsSNP was amplified from a range of BCG, M. bovis and M.
tuberculosis strains using Forward (ACCGTCCACACGTACATTTG)
and Reverse (AGCGTGGACTTGAGTCTATG) primers (MWG).
DNA from heat-killed mycobacterial cells was used as a template
for the amplifications, with DNA polymerase HotStar Taq (Qiagen).
The PCR cycle conditions were 95 uC for 15 min, followed by 30
cycles of 95 uC for 1 min, hybridization for 1 min at 58 uC, extension
for 1 min at 72 uC and a final incubation at 72 uC for 5 min. The
PCR product was purified and the point mutation was confirmed by
cycle sequencing (Sequencing Service, University of Dundee, UK).
Modelling of the Rv3124 structure. The GenTHREADER program
at the PSIPRED server (Bryson et al., 2005; Jones, 1999) was used to
identify and align proteins structurally related to Rv3124. Only one
protein with high resemblance (approximately 50% sequence
identity) was retrieved from the search. This was EmbR, a
transcriptional regulator from M. tuberculosis (PDB id: 2FF4)
(Alderwick et al., 2006). Sequence alignment with EmbR was used
to obtain a model of Rv3124 structure from the Swiss-model server
(Kiefer et al., 2009). Protein structures were analysed with the Swiss-
PDP Viewer (http://spdbv.vital-it.ch/).
Complementation of M. bovis BCG with bcg3145 and rv3124.
Using pSM96 as a vector (an E. coli–mycobacteria shuttle vector
containing a hsp60 promoter upstream of a multiple cloning site,
constructed by Dr S. Michell, VLA Weybridge), constructs were
generated with rv3124 (pB1) or bcg3145 (pB3, Table 1). For pB1,
rv3124 was amplified from M. tuberculosis H37Rv genomic DNA and
for pB3, M. bovis BCG genomic DNA. PCRs used primers
Rv3124BamF (ATGGGATCCGTGCAATTCAACGTCTTAGGACC-
ACTGGAAC, BamHI site underlined) and Rv3124PstR (CATCTG-
CAGTTATGCCAAACCGATGGGAAGGAG, PstI site underlined).
The amplification conditions were 94 uC for 15 s, then 30 cycles of
1 5sa t9 4uC, hybridization and extension at 68 uC for 3 min, then a
final extension for 3 min at 68 uC. pSM96 and PCR products were
digested with BamHI and PstI, ligated following standard protocols,
and transformed into E. coli. Sequencing was used to confirm the
correct sequence and orientation of the cloned fragments. Plasmid
constructs were purified from E. coli and electroporated into M. bovis
BCG Pasteur using standard methods, with transformants selected on
7H11 plates containing kanamycin and hygromycin. Isolated colonies
were selected from the plates, checked for the presence of the plasmid
by PCR, and then grown in 7H9 containing the appropriate antibiotic
for transcriptome analysis.
Transcriptome analysis. Strains were grown in 7H9-ADC medium
with 0.05% Tween 80 to an OD600 of #0.6, corresponding to mid-
exponential growth. Each strain was cultured three times (three
biological replicates), with each culture split in two and RNA
extracted (two technical replicates; hence six microarrays in total per
strain). Total RNA from each strain was extracted, purified, reverse-
transcribed, and labelled with Cy5-dCTP (Amersham Pharmacia) as
previously described (Golby et al., 2007). Cy3-labelled DNA (M. bovis
AF2122/97 and M. tuberculosis H37Rv) was used as a control. Probes
were hybridized to whole-genome M. bovis/M. tuberculosis composite
microarrays and scanned with an Affymetrix 428 scanner. The
microarrays were developed by the Bacterial Microarray Group (St
Georges, University of London) in collaboration with the Veterinary
Laboratories Agency (Weybridge). The array design is available in
BmG@Sbase (accession no. A-BUGS-31; http://bugs.sgul.ac.uk/A-
BUGS-31) and also ArrayExpress (accession no. A-BUGS-31). Fully
annotated microarray data have been deposited in BmG@Sbase
(accession no. E-BUGS-93; http://bugs.sgul.ac.uk/E-BUGS-93) and
also ArrayExpress (accession no. E-BUGS-93). Image processing and
data normalization steps were performed as previously described
(Golby et al., 2008).
To select differentially expressed genes between strains, a t-test was
applied to each gene, with the Benjamini and Hochberg False
Discovery Rate applied to adjust P-values and correct for multiple
testing. Those differentially expressed genes (adjusted P-value ,0.05)
showing an expression difference greater than threefold between
strains were selected for further investigation. Results for these genes
were confirmed by quantitative reverse transcription PCR (qRT-PCR)
analysis, as previously described (Golby et al., 2007). Briefly, RT-PCR
was carried out using the QuantiTecT SYBR Green PCR kit (Qiagen).
Each reaction was carried out in a 25 ml volume containing 12.5 ml
QuantiTect Master Mix, 0.4 mM of each primer and 5 ml diluted
cDNA. All reactions were run in duplicate using a RotorGene 3000
instrument (Qiagen). The instrument was programmed to cycle at
50 uC for 30 min; 95 uC for 15 min; and then 50 cycles of 15 s at
95 uC, 30 s at 55 uC and 30 s at 60 uC. For each reaction the melting
curve was analysed and the PCR product was run on an agarose gel in
order to confirm the specificity of the RT-PCR. Expression levels were
normalized using the sigA gene as an internal reference. Primers used
for qRT-PCR are listed in Supplementary Table S1, available with the
online version of this paper.
Construction of an M. bovis BCGDbcg3145 knockout.
Generation of the M. bovis BCGDbcg3145 followed a previously
described phage protocol (Bardarov et al., 2002), with bcg3145
disrupted by a hygromycin cassette using a shuttle phasmid. Briefly,
an approximately 1 kb region flanking bcg3145 was amplified by PCR.
For the downstream region, the primers RIGHT PBCGPPEF
(ATGAAGCTTCTACGCCCCTCAATGCAAGCG; HindIII site under-
lined) and PBCGPPER (ATACTAGTCAGCTGGCGGCCATTCA-
GGCTC; SpeI site underlined) were used; after HindIII and SpeI
digestion the fragment was cloned into the cosmid pYUB854, to
generate p3145right. The upstream region of bcg3145 was amplified
using the primers PBCG3144F (ATTCTAGAGGCGGTCAACGAG-
GCGATCTGC; XbaI site underlined) and PBCG31444R (ATTC-
TAGAAGCACCTGCCGTCGTTGCGTTC; XbaI site underlined);
after XbaI digestion this fragment was cloned into p3145right to
generate the cosmid p3145KO. The correct orientation of the
fragments was determined by restriction enzyme digestion and
sequencing. The in vitro packaging reaction of the cosmid was done
by PacI digestion and using the in vitro packaging kit Giga XL
(Stratagene). After transduction of E. coli HB101 cells, transductants
were selected on plates containing hygromycin and positive colonies
were checked by PacI digestion.
M. smegmatis mc
2155 was transformed with purified phasmid DNA
by electroporation followed by selection on agar plates for 4 days at
30 uC. The phages generated were titrated, and a ratio of 10 phage per
bacterium was used for the transduction of M. bovis BCG at the non-
permissive temperature of 37 uC. Hygromycin-resistant transfor-
mants were screened for loss of bcg3145 by PCR and Southern blot
analysis. Southern blotting (see Supplementary Fig. S1) was
performed using a non-radioactive 435 bp probe and the DIG High
Prime DNA Labelling and Detection Starter kit II (Roche Applied
Science).
Site-directed mutagenesis. Site-directed mutagenesis (SDM) on
rv3124 was carried out using the Stratagene Quikchange II XL site-
directed mutagenesis kit. The primer pairs used are listed in
Supplementary Table S2. As a template for the reaction, rv3124 was
cloned into the BamHI and PstI sites of pUC19 after amplification
P. Mendoza Lopez and others
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CTTAGGACCACTGGAAC) and Rv3124PstR (CATCTGCAGTTA-
TGCCAAACCGATGG GAAGGAG), generating pUC3124. The SDM
reactions were carried out in a total volume of 50 ml containing 5 ml
reaction buffer, 10 ng pUC3124, 125 ng of each oligonucleotide, 1 ml
dNTP mix and 2.5 units Pfu Ultra HF DNA polymerase. The
thermocycling programme used was 95 uC for 30 s, followed by 16
cycles of 95 uC for 30 s, 55 uC for 1 min, and 68 uC for 5 min. After
cooling the tubes on ice for 2 min, template was degraded using 10
units DpnI restriction enzyme at 37 uC for 1 h. One microlitre of each
reaction was used to transform competent E. coli XL1-Blue cells and
transformants were selected on LB-ampicillin plates. Mutant colonies
were isolated and sequences verified (DNA Sequencing & Services,
University of Dundee, UK).
Purification of recombinant Rv3124. To purify Rv3124, MBPpET,
an in-house double fusion tag vector (Vircell), was used using an
MBP-Rv3124-His6 orientation with the maltose-binding protein
(MBP) solubility enhancer and a 6-His tag flanking Rv3124. Fusion
of rv3124 to MBPpET was accomplished using PCR to generate DNA
fragments from M. tuberculosis gDNA containing BamHI and XhoI
sites. The resulting DNA fragments were ligated to the BamHI and
XhoI sites of the MBPpET vector. Correct nucleotide sequence was
confirmed by DNA sequencing performed at the ‘Lopez Neyra’
Institute of Parasitology and Biomedicine in Granada, Spain. For
expression of the MBP-Rv3124-His fusion protein, the construct was
transformed into E. coli BL21 (Invitrogen), grown at 37 uCi nL B
containing 50 mg kanamycin ml
21 to an OD600 of 0.6, and protein
expression was induced with the addition of IPTG and arabinose to a
final concentration of 1 mM and 0.2% respectively, with cultures
then grown for an additional 3 h. Cells were harvested by
centrifugation at 1789 g, and pellets that were not used immediately
were frozen at 280 uC. For the scale-up purification procedure,
frozen pellets from 1 l of BL21 cells overproducing Rv3124 were
thawed and resuspended in lysis buffer [200 mM Tris/HCl (pH 7.5),
200 mM sodium chloride, 1 mM EDTA and 10 mM b-mercaptoeth-
anol]. Cells were lysed using a French press cell disrupter (Thermo).
The crude extract was centrifuged at 50000 g for 30 min at 4 uC, and
the Rv3124 protein present in the supernatant was purified using
Amylose Resin matrix according to the manufacturer’s instructions
(New England Biolabs). Final protein concentration was determined
using a Bradford Protein Assay kit (Bio-Rad) with BSA (Pierce) as a
standard.
Electrophoretic mobility shift assay (EMSA). EMSAs were
performed using a 222 bp DNA fragment (Rv3109pro) containing
190 bp upstream of the moaA1 gene and the first 32 bp of the moaA1
gene. The Rv3109pro fragment was generated by PCR using the
primers F1 (AACGAAAGCTCGCACATGAGTGGTC) and R3 (ATG-
GAGCTACCATATCAGGCAG), and end-labelled with [c-
32P]dATP
Table 1. Bacterial strains and plasmids used in this study
Bacterial strain/plasmid Relevant genotype or characteristics Reference or source
M. bovis BCG Pasteur strain VLA Weybridge, UK
M. bovis AF2122/97 Virulent isolate from a cow in Cornwall, UK VLA Weybridge, UK
M. tuberculosis H37Rv Virulent strain isolated in 1905 VLA Weybridge, UK
M. smegmatis mc
2155 Mutant with high plasmid transformation efficiency Professor W. R. Jacobs, AECOM,
NY, USA
M. bovis BCG Dbcg3145 Knockout strain of M. bovis BCG Pasteur with bcg3145 gene replaced by
hygromycin cassette
This study
E. coli DH5a General cloning strain Invitrogen
E. coli BL21(DE3) Strain used for protein expression Invitrogen
E. coli HB101 General cloning strain Invitrogen
E. coli XL1-Blue General cloning strain Invitrogen
pUC19 General cloning vector VLA Weybridge
pUC3124 pUC19 containing rv3124 This study
pSM96 Mycobacterial expression vector with hsp60 promoter VLA Weybridge, UK (Wooff et al.,
2002)
pB1 rv3124 in pSM96 This study
pB3 bcg3145 in pSM96 This study
MBPpET MBP–His fusion vector used in protein purification Vircell
pYUB854 Cosmid vector used for mutant construction; contains the hygromycin
cassette and a multiple cloning site
Bardarov et al. (2002)
p3145KO Cosmid used in the bcg3145 knockout containing the gene flanking
regions into pYUB854
This study
pSM128 Mycobacteriophage L5-based vector carrying a lacZ reporter Dussurget et al. (1999)
pB31 190 bp upstream of rv3109 in pSM128 This study
pB32 116 bp upstream of rv3109 in pSM128 This study
pB33 45 bp upstream of rv3109 in pSM128 This study
pB10 G90A mutation in the DNA-binding domain This study
pB11 Y91A mutation in the DNA-binding domain This study
pB15 E159I mutation in the BTA domain This study
pB17 E159W mutation in the BTA domain This study
pB23 E159D mutation in the BTA domain This study
pB25 E159Q mutation in the BTA domain This study
MoaR1 transcriptional regulator
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contained 1 ml BSA, 1 ml poly (dI–dC), 1 ml1 0 6 binding buffer
(40% glycerol, 50 mM DTT, 500 mM NaCl, 100 mM Tris/HCl,
pH 7.5, 10 mM MgCl2, 5 mM EDTA), purified Rv3124 protein of
varying concentrations and a constant concentration of labelled
substrate DNA. When indicated, unlabelled Rv3109 probe was added
as competitor DNA in a 10-fold and 100-fold molar excess. After
incubation at 37 uC for 30 min, protein-bound and free DNA were
separated by electrophoresis at ambient temperature on a 4.5% native
polyacrylamide gel running at 7 mA for 3 h. The gels were dried for
2 h and exposed to X-ray film overnight or longer at 280 uC.
Analysis of promoter activity. rv3109 (moaA1) promoter PCR
fragments were cloned upstream of lacZ in the L5-based integrating
vector pSM128 (Dussurget et al., 1999), and then sequenced to verify
the sequence and correct orientation of the promoter–lacZ fusions.
To generate constructs, three forward primers were used, namely Fg1
(TAGTACTAACGAAAGCTCGCACATGAGTGGTC; ScaI site under-
lined), Fg2 (TAGTACTCCACGATGCGCCGATGCATTTCGG) and
Fg3 (TAGTACTTAACCGACTGCGTCCAAAGT), and one reverse
primer, Rev (TAGTACTATGGAGCTACCATATCAG). PCR products
and pSM128 were ScaI digested and ligated to generate pB31, pB32
and pB33, respectively. Plasmids were electroporated into M.
smegmatis mc
2155 previously transformed with pB1, and kanamycin-
and streptomycin-resistant transformants were isolated. Three
independent transformants of each construct were selected for
measurements of promoter activity. Cell extracts were prepared using
a previously described method (Sala et al., 2008). b-Galactosidase
assays were performed on M. smegmatis mc
2155 cells grown at 37 uC
to OD600 1. Cells were collected by centrifugation, resuspended in
500 ml TEDP (0.1 M Tris/HCl, 1 mM EDTA, 1 mM DTT and 1 mM
PMSF), and disrupted by sonication using two pulses of 20 s at 40%
amplitude (Bandelin Sonoplus GM 70). b-Galactosidase activity was
assayed as described by Miller (1972). M. smegmatis transformed with
promoter-probe vector alone (pSM128) was used as a negative
control. The enzyme activities were expressed as nmol ONPG
converted to o-nitrophenol min
21 (mg protein)
21.
RESULTS
The bcg3145 SNP was an early event in the
derivation of M. bovis BCG
The E159G SNP in bcg3145 is present in the genome-
sequenced strain M. bovis BCG Pasteur 1173P2 relative to
the virulent sequenced strains M. tuberculosis H37Rv and M.
bovis AF2122/97 (the nucleotide sequences of the mb3147
and rv3124 orthologues are 100% identical). In order to
confirm the presence of this mutation in other BCG strains
by conventional sequencing, the gene was amplified and
sequenced from ‘early’ and ‘late’ BCG strains (Behr et al.,
1999). The bcg3145 sequence from all M. bovis BCG strains
tested (Pasteur, Denmark, Frappier, Russia, Tokyo, Sweden
and Tice) differed from the M. bovis or M. tuberculosis
orthologues in an adenine to guanine nsSNP that produces a
glutamic acid to glycine change in amino acid residue 159 of
the mature protein (E159G) relative to the orthologue in
virulent strains (see Supplementary Fig. S2). Using BLAST we
also identified the non-mutated residue in other genome-
sequenced M. tuberculosis strains (CDC1551, KZN 1435, C,
Haarlem, F11 and H37Ra). Therefore the E159G mutation
was an early event during the derivation of BCG.
Modelling the structure of Rv3124 and predicted
effects of the E159G mutation
To assess the functional consequences of the E159G
mutation on Rv3124/BCG3145, the structure of Rv3124
was modelled using M. tuberculosis EmbR as the template.
The sequences of these two proteins share 54% identity and
73% similarity. The resulting model (Fig. 1a) shows that
Rv3124 is a two-domain protein composed of an amino-
terminal DNA-binding domain (DBD) and a carboxy-
terminal bacterial transcriptional activation (BTA) domain,
the same modular arrangement as present in other members
of the SARP family of transcription factors, such as
Streptomyces peuceticus DnrI (Sheldon et al., 2002). Rv3124
lacks domains present in some other SARP proteins, such as
forkhead-associated domains (Alderwick et al., 2006).
Residue E159 is located in the third a-helix of the BTA
domain of Rv3124 (Fig. 1b). The replacement of glutamic
Fig. 1. (a) Rv3124 structural model based on the EmbR molecular
structure. The DNA-binding domain is in green, and the BTA
domain in purple. Residue E159, located in the third a-helix of the
BTA domain, is shown in red. (b) Close-up of the third a-helix of
the BTA domain from a different angle. The side chains of residues
that form the helix are in blue, except for E159, which is shown in
red. Intra-chain H bonds are represented by green dashed lines.
Replacement of Glu159 by Gly perturbs the helix.
P. Mendoza Lopez and others
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therefore would be predicted to have functional effects on
the activity of BCG3145.
Transcriptome analysis
In order to define the function of BCG3145/Rv3124, the M.
tuberculosis regulator was overexpressed in M. bovis BCG
Pasteur under the control of the hsp60 promoter, and the
effect on the transcriptome analysed using microarrays and
qRT-PCR. Overexpression of bcg3145 or rv3124 in BCG did
not result in any change in the in vitro growth profile of the
recombinant BCG strains in 7H9 liquid medium compared
with wild-type BCG (data not shown). The results obtained
from microarray analyses showed that 10 genes were
significantly overexpressed and 11 genes were down-
regulated (minimum of threefold differential expression)
when rv3124 was overexpressed in M. bovis BCG (Table 2)
compared with a vector-only control. A cluster of six
differentially expressed genes were localized in the moa1
locus of the M. bovis BCG genome, including the moa1
locus: moaA1 (rv3109), moaB1 (rv3110), moaC1 (rv3111)
and moaD1 (rv3112). To validate the microarray data for
those genes with upregulated expression, qRT-PCR analysis
was performed. Fig. 2 compares the fold changes in
expression in M. bovis BCG measured by microarray and
qRT-PCR for the moa1 locus. The two methods displayed
broad agreement in expression levels for each gene,
confirming the experimental procedures and statistical
approaches used in this study. Overexpression of rv3124 in
M. tuberculosis H37Rv also led to upregulation of the moa1
locus as determined by microarray analysis (data not
shown).
M. bovis BCG Dbcg3145 mutant construction
To assess the effects of inactivation of BCG3145 on M. bovis
BCG, a knockout mutant was generated by inserting a
hygromycin cassette into the bcg3145 gene. Allelic exchange
was confirmed in M. bovis BCG by PCR (data not shown)
and Southern blotting (Supplementary Fig. S1). To initially
characterize the M. bovis BCG Dbcg3145 mutant strain, the
growth profiles of the knockout and the wild-type were
measured under standard in vitro culture conditions and
they showed similar doubling times (data not shown). As
our transcriptome analysis had shown that the moa1 locus
was regulated by Rv3124, we measured the expression of
these genes in the wild-type and mutant by qRT-PCR, and
no significant difference was found. This was probably to be
expected, as BCG3145/Rv3124 both show low-level expres-
sion in mid-exponential-phase cultures of M. tuberculosis or
M. bovis BCG (Brosch et al., 2007; Golby et al., 2007).
Effect of the BCG3145 mutation on transcription
of the moa1 locus
To elucidate the effects of the E159G SNP on the function of
the transcriptional regulator BCG3145, M. bovis BCG was
complemented with a plasmid overexpressing bcg3145 or
wild-type rv3124 under the hsp60 promoter. Comparison of
globalexpressionacrossthesetwo strainsbymicroarrayanal-
ysis revealed a set of differentially expressed genes (Table 3).
As the expression level of Rv3124 was not equal across the
Table 2. Microarray identification of differentially expressed
genes in BCG overexpressing Rv3124 compared with BCG/
pSM96 vector control
Rv no. Gene Product Fold
change*
rv0991 Hypothetical protein 3.0
rv2428 ahpC Alkyl hydroperoxide reductase C 5.4
rv2636 Hypothetical protein 3.4
rv2931 ppsA Phenolpthiocerol synthesis 3.0
rv3109 moaA1 Molybdopterin biosynthesis 36.8
rv3110 moaB1 Molybdopterin biosynthesis 21.5
rv3111 moaC1 Molybdopterin biosynthesis 16.4
rv3112 moaD1 Molybdopterin biosynthesis 9.3
rv3113 Conserved phosphatase 15.2
rv3114 Hypothetical protein 5.1
rv0823c Transcriptional regulator 0.26
rv0824c desA1 Fatty acid desaturase 0.33
rv1094 desA2 Fatty acid desaturase 0.31
rv1798 Conserved hypothetical protein 0.32
rv2836c dinF DNA-damage-inducible protein 0.33
rv2987 leuD 3-Isopropylmalate dehydratase 0.33
rv2988 leuC 3-Isopropylmalate dehydratase 0.16
rv2989 Transcriptional regulator 0.18
rv3212 Alanine-valine-rich protein 0.32
rv3229c desA3 Fatty acid desaturase 0.32
rv3919 gid Glucose-inhibited division protein 0.28
*Values ,1 are downregulated in BCG overexpresssing Rv3124
compared with BCG/pSM96.
Fig. 2. Confirmation of microarray results by qRT-PCR. The moa1
locus showed a higher level of expression in M. bovis BCG
overexpressing Rv3124 than M. bovis BCG wild-type as
measured by microarray (white bars) and by qRT-PCR (black
bars). Fold changes are the mean ratios±SD of gene expression
from two independent experiments.
MoaR1 transcriptional regulator
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normalize fold changes to Rv3124 expression levels. The final
normalized fold change was therefore calculated by dividing
the BCG/pB1 versus BCG/pB3 fold changes by 2.84, the
increased level of expression of Rv3124 seen in the BCG/pB1
compared with BCG/pB3. Overexpression of Rv3124 pro-
duced an 8.5- to 2.77-fold higher level of induction of the
genes in the moa1 locus compared with BCG3145 (Table 3).
The microarray results were confirmed by qRT-PCR (see
SupplementaryTableS3).Henceitappearsthatthemutation
in BCG3145 reduces the ability of the regulator to induce
expression of the moa1 locus.
EMSA and moaA1 promoter characterization
Specific in vitro binding of Rv3124 to the rv3108–moaA1
region was assessed by EMSAs. We evaluated binding of
Rv3124 to an intergenic region of 202 bp, upstream of
moaA1/rv3109, which was selected as a putative binding
sequence (Fig. 3a). Purified Rv3124 bound to radiolabelled
Rv3109pro promoter probe DNA and retarded its mobility
(Fig. 3b). The extent of binding increased with Rv3124
protein concentration, with a mobility shift detected using
0.15 mg protein. Binding to the labelled promoter could be
specifically competed with a 10 and 100-fold excess of the
corresponding unlabelled DNA. Bioinformatic screens for
regulatory binding motifs upstream of rv3124 and moaA1
did not reveal any significant matches.
To further define the sequence elements recognized by
Rv3124, we conducted EMSAs with 59 deleted fragments of
the rv3109 promoter, and generated promoter-reporter
vector constructs. For the latter, fragments of 190 bp,
116 bp and 45 bp upstream of moaA1 were cloned into the
promoterless integrative vector pSM128 (see Methods),
creating transcriptional fusions with the b-galactosidase
gene (Dussurget et al., 1999); these constructs were then
transformed into a M. smegmatis strain overexpressing
Rv3124, and reporter activity measured (Fig. 3c). b-
Galactosidase activity of all constructs was significantly
higher than that for the control pSM128; however, b-
galactosidase background was seen in recombinants with
the 190 bp fragment–lacZ fusion in the absence of Rv3124
overexpression, possibly due to read-through or to the
presence of a functionally similar transcriptional regulator
in M. smegmatis. Nevertheless, the presence of Rv3124
increased the promoter activity threefold. The levels of
expression of the 116 bp construct were approximately
50% lower than those showed for the 190 bp fragment.
The smallest fragment (45 bp) generated only background
activity levels.
EMSA was performed with Rv3124 and the same moaA1
promoter fragments as used in the b-galactosidase assays
(Fig. 3d). Fragments were generated by PCR amplification
using the same primern pairs as used for the promoter-
probe vector construction and gel-purified. Bound protein
was detected using the larger fragment Rv3109pro-190 bp.
The Rv3109pro-116 bp probe was weakly bound by
protein, and no binding was detectable with the
Rv3109pro-45 bp probe. Thus Rv3124 binds directly to
the moaA1 promoter.
Rv3124 domain characterization
The E159G mutation in BCG3145 occurs in the BTA
domain of BCG3145. The transcriptome results from
strains overexpressing BCG3145 or Rv3124 suggested that
the E159G SNP had a subtle effect on gene regulation, so
we sought to determine how other mutations at the E159
Table 3. Genes differently expressed in BCG overexpressing Rv3124 (BCG/pB1) or BCG3145 (BCG/pB3)
Rv Gene BCG/pB1* BCG/pB3 Fold change without
normalization to
Rv3124 expression
level
Normalized
fold changeD
Expression
level (log2)
Minimum
level (log2)
Maximum
level (log2)
Expression
level (log2)
Minumum
level (log2)
Maximum
level (log2)
rv2933 ppsC 20.45 20.51 20.35 22.17 22.41 22.06 3.39 1.15
rv2932 ppsB 20.69 20.81 20.62 20.35 20.44 20.32 3.08 2.35
rv3058 1.69 1.57 1.89 0.07 0.05 0.08 3.28 1.08
rv3109 moaA1 1.87 1.56 2.02 22.70 22.86 22.64 23.91 8.41
rv3110 moaB1 2.29 2.16 2.43 22.31 22.48 22.08 24.36 8.57
rv3111 moaC1 0.97 0.95 1.12 22.88 22.94 22.45 14.51 5.11
rv3112 moaD1 1.62 1.43 1.97 21.35 21.71 21.06 7.89 2.77
rv3113 0.57 0.35 0.74 22.89 23.26 22.83 11.02 3.88
rv3114 0.24 0.13 0.32 21.67 21.81 21.18 3.78 1.33
*Expression levels for each gene are the median of three independent microarray experiments. Minimum and maximum expression levels for the
three replicates are shown.
DRv3124 was expressed 2.84-fold higher in BCG/pB1 compared to BCG/pB3.
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functionally important residues, BCG3145/Rv3124 was
compared with other SARP family member proteins
(Supplementary Fig. S2). Previously it had been shown
that alanine substitution of the conserved residues G90 and
Y91 in the DBD of the related SARP-family regulator DnrI
abrogated protein–DNA binding (Sheldon et al., 2002), so
we sought to determine whether similar mutations in
Rv3124 would block its activity.
Residues G90, Y91 and E159 in Rv3124 were subjected to
site-directed mutagenesis. The range of mutations gener-
ated was G90A, Y91A, E159I, E159W, E159D, E159Q. The
mutant proteins were overexpressed in the M. bovis
BCGDbcg3145 knockout strain to ensure no interference
from a chromosomal copy of the gene, and alterations in
the transcription levels of the moa1 locus were determined
by qRT-PCR, normalizing the moa1 levels in the different
strains to the mutated Rv3124 expression levels. Fig. 4(a)
Fig. 3. Binding of Rv3124 to the rv3108–moa1A intergenic region. (a) The moaA1 locus showing locus organization and
positions of oligonucleotides used in EMSA and lacZ fusions. Primers F1 and R3 were used to generate the Rv3109pro
product used in EMSA assays; primers Fg1, Fg2, Fg3 and Rev were used to generate products for lacZ-transcriptional fusions.
(b) EMSA was performed in the absence of Rv3124 (lane 1) or in the presence of 0.15, 0.3, 0.6 or 1.2 mg purified Rv3124
(lanes 2–5). Competition was performed with Rv3124 (2.4 mg) with no competitor (lane 6) or with unlabelled specific
competitor rv3109 probe (10-fold and 100-fold molar excess, lane 7 and lane 8, respectively). (c) b-Galactosidase activity of
promoter-probe constructs in wild-type M. smegmatis mc
2155 (denoted by ‘”’) and M. smegmatis overexpressing Rv3124
(denoted by ‘+’). Activity was monitored by plating strains on medium containing X-Gal and by quantitative b-galactosidase
assay. Data are shown as Miller units, and are the mean±SD of three replicates. (d) Binding assay with full-length and truncated
versions of the Rv3109pro probe (190 bp, 116 bp and 45 bp) in the absence of Rv3124 (lane 1) or in the presence of 0.6 mg
and 1.2 mg Rv3124 (lanes 2 and 3 respectively). Decreased Rv3124 binding to the shorter probes correlates with reduced b-
galactosidase activity in the corresponding lacZ transcriptional fusions.
MoaR1 transcriptional regulator
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Pasteur strains overexpressing mutated versions of Rv3124
compared with BCG overexpressing the non-mutated
Rv3124.
The mutations introduced in the DBD had divergent
effects on protein function. While the G90A substitution
had no effect on the transcription of the moa1 locus, the
Y91A mutation significantly reduced locus transcription.
This would appear to conflict with the previously reported
results obtained with the DnrI regulator (Sheldon et al.,
2002). To determine the structural basis for these results,
the G90A and Y91A mutations were mapped to the Rv3124
structural model (Fig. 4b). The DBD domain is highly
conserved among gene regulators of the OmpR/PhoB
family (Alderwick et al., 2006), and is formed by a three-
helix bundle flanked by two b-sheets. Residues G90 and
Y91 are located in one of the two sheets. The role of G90
seems not to be critical since the bend in the short coil
intersection between the two strands that form the sheet is
maintained by two contiguous conserved prolines at
positions 88 and 89. Therefore the mutation G90A does
not have a significant effect on the activity of the protein.
On the other hand, residue Y91 seems to have a more
important function in the overall stability of the DBD by its
interaction with another conserved residue (H63) located
in a neighbouring helix. Hence the change of tyrosine to
alanine in Y91A causes a perturbation of the local structure
that compromises binding to DNA, thus explaining the
decrease in the induction of the moa1 locus by the Y90A
variant of Rv3124.
To assess the importance of residue 159 in the BTA
domain, several mutations were introduced. First, we were
interested in evaluating the effect of a complete change in
residue properties; hence, glutamic acid was replaced with
isoleucine or tryptophan. These mutations completely
disrupted protein function, as shown by the dramatic
decrease of RNA levels for the moa1 locus (Fig. 4a). To
assess the functional effect of more subtle changes, Glu159
was substituted with aspartic acid or glutamine. qRT-PCR
analysis revealed that the aspartic acid mutation did not
significantly alter protein function, with the E159D Rv3124
protein being able to complement the knockout strain to
wild-type levels. However, complementation with the
E159Q mutated version of Rv3124 was not able to induce
the moa1 locus to the same degree as the wild-type protein.
Again using the Rv3124 structural model to map the
mutations, it was evident that E159G, E159I and E159W
caused a perturbation of the helix that affects the function
of the BTA domain. Mutations E159D and E159Q have a
lesser effect on the structure and hence maintain the
functionality of the domain.
DISCUSSION
Comparison of the genome of M. bovis BCG Pasteur with
those of M. bovis and M. tuberculosis has revealed a range of
deletions and SNPs between the vaccine strain and virulent
tubercle bacilli that may play a role in the virulence
attenuation of BCG. However, while clear functional links
have been made for some mutations in BCG, such as the
RD1 deletion or SNPs in the mmaA3 and pykA genes,
linking genetic differences to phenotypic changes is far
from trivial.
A comprehensive survey of SNP differences across BCG
vaccine strains and M. bovis strains from the UK and
France revealed 186 SNPs that differentiated virulent M.
bovis from BCG, with 115 of these SNPs being non-
synonymous. An amplification of this mutational differ-
ence is achieved when nsSNPs occur in regulatory genes, as
perforce each one affects the expression of a wide range of
genes. Amongst these nsSNPs was a mutation in bcg3145,
encoding a putative transcriptional regulator of the AfsR/
DnrI/SARP family. The predicted secondary structure of
BCG3145 revealed that the protein consists of two
conserved domains. The N-terminal region is a DNA-
Fig. 4. (a) Fold change in expression of the moa1 locus in BCG
strains overexpressing mutated versions of Rv3124. The expres-
sion of the moa1 locus in BCG strains complemented with the
mutated Rv3124 was compared with M. bovis BCG overexpres-
sing the non-mutated Rv3124. Data from two independent
experiments for each strain were first normalized to Rv3124 and
then normalized to sigA RNA levels. (b) Residues G90 and Y91
(depicted in blue) are located in one of the two b-sheets that form
the DBD of Rv3124. Residue G90 seems not to be critical,
explaining why its mutation had no effect on the regulator’s activity.
However, residue Y91 interacts with a conserved residue (H63)
located in a neighbouring helix, showing why mutation of this
residue in MoaR1 caused a decrease in the induction of the moa1
locus.
P. Mendoza Lopez and others
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packed against two antiparallel b-sheets forming a winged
helix–turn–helix (Martinez-Hackert & Stock, 1997a), and a
C-terminal region (residues 97–270) which is a BTA
domain formed with seven a-helices (Alderwick et al.,
2006). It has been suggested that the region of a-loop
connecting the recognition helix a3 and the positioning
helix a2, which are conserved in the DNA-binding domain
of the SARP family, interacts with the C-terminal domain
of the a subunit of RNA polymerase (Martinez-Hackert &
Stock, 1997b; Tanaka et al., 2007). The E159G mutation in
BCG3145 mutates to glycine a conserved glutamic acid
residue located in a tetratricopeptide repeat (TRP) in the
BTA domain (region T3). TRP domains are associated with
protein–protein interactions (D’Andrea & Regan, 2003),
while a conserved core (helices T1–T7) of the BTA domain
seems to be required for proper function of SARP family
proteins (D’Andrea & Regan, 2003; Sheldon et al., 2002).
In the present study we found that BCG3145/Rv3124 is a
positive transcriptional regulator of the moa1 locus,
promoting the expression of the moaA1B1C1D1 genes
required for molybdopterin biosynthesis. Microarray results
were confirmed independently by qRT-PCR, while direct
binding of Rv3124 to the upstream region of moaA1, the
first gene of the moa1 locus, was confirmed by EMSAs. The
moaA1B1C1D1 genes encode key enzymesin the synthesisof
molybdopterin, a pterin-based molybdenum-binding cofac-
tor of molybdoenzymes such as nitrate reductase. MoaA1
and MoaC1 are predicted to catalyse the conversion of GTP
into cyclic pyranopterin monophosphate (cPMP), the first
step in the synthesis of molybdopterin; cPMP is then
converted to the metal-binding pterin dithiolate by
molybdopterin synthase, a heterotetrameric complex of
MoaD1 and MoaE1 (Rv3119). MoaB1 is predicted to be
involved in insertion of molybdenum into molybdopterin to
form the molybdenum cofactor (Schwarz et al. 2009).
In E. coli, the moa operon shows increased expression under
anaerobiosis (Baker & Boxer, 1991), a situation which
requires the production of several essential molybdoenzymes
foranaerobicrespiration(Selfetal., 1999). Oxygen limitation
is considered to be a key factor affecting the metabolism of
M. tuberculosis in the hypoxic environment of the granuloma
(Parish & Brown, 2008). In genome-wide expression analysis
of M. tuberculosis isolated from lung biopsy samples, a 13-
fold upregulation of rv3124 was observed in granuloma
tissues of patients with active tuberculosis compared
with in vitro cultures of M. tuberculosis (Rachman et al.,
2006). This condition is reproduced in vitro by the Wayne
model (Wayne & Hayes, 1996), where oxygen is depleted
gradually and M. tuberculosis growth shows two phases, a
microaerobic state, called nonreplicating persistent stage 1
(NRP-1), and an anaerobic stage, NRP-2. rv3124 has been
shown to be upregulated in both NRP-1 and NRP-2 states in
M. tuberculosis compared with aerobic roller cultures
(Muttucumaru et al.,2 0 0 4 ) .H e n c e ,r e g u l a t i o no frv3124
appears to be modulated by oxygen availability.
Sequence alignments and protein modelling suggested that
the E159G mutation in BCG3145 would have structural
consequences, with microarray analysis showing that the
mutation had a subtle effect on the ability of BCG3145 to
activate moa1 locus transcription. Overexpression of
mutated variants of Rv3124 in BCG, with subsequent
qRT-PCR on the constituent genes of the moa1 locus,
showed that E159I and E159W substitutions had profound
effects on protein function, as would be expected, with
E159Q showing more subtle effects, while mutation of the
Tyr91 reside in the DNA-binding domain also abrogated
the regulator’s activity.
Conclusion
We have identified Rv3124 as a positive regulator of
molybdopterin biosynthesis, and defined the functional
consequences of a mutation in the BCG3145 orthologue.
As Rv3124 regulates expression of the moa1 locus, we
suggest that rv3124 be renamed moaR1. The E159G
mutation in BCG3145 was shown to decrease, but not
abolish, the ability of the regulator to induce expression of
the moa1 locus. Given our results, and the fact that Rv3124
was not identified as a virulence factor in M. tuberculosis
using saturation mutagenesis screens (Sassetti & Rubin,
2003), it would appear that the mutation in BCG3145 is
not a key attenuating genetic lesion in BCG.
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